Does the lack of left ventricular reverse remodeling always mean non - response to cardiac resynchronization therapy?
- Authors: Kuznetsov VA1, Soldatova AM1, Enina TN1, Krinochkin DV1, Dyachkov SM1
-
Affiliations:
- Tyumen Cardiology Research Center - Branch of Tomsk National Research Medical Center, Russian Academy of Science
- Issue: Vol 91, No 12 (2019)
- Pages: 10-15
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33727
- DOI: https://doi.org/10.26442/00403660.2019.12.000102
- ID: 33727
Cite item
Full Text
Abstract
Aim. To evaluate clinical, morphological, functional features and mortality level in patients with different value of left ventricular reverse remodeling after cardiac resynchronization therapy (CRT). Materials and methods. The study enrolled 112 patients (mean age 54.6±9.9 years, 83.5% men) with left ventricular ejection fraction (LVEF) І35%, NYHA functional class II-IV. We enrolled patients with QRS width >120 ms or QRS <120 ms + 3 parameters of mechanical dyssynchrony by echocardiography. Clinical, electrocardiographic and echocardiographic parameters were evaluated at baseline, 1, 3 months and each 6 months after implantation. Three patients with increase of left ventricular end - systolic volume (LVESV) were excluded from prospective trial due to lack of full follow - up data. According to the best decrease of LVESV (mean follow - up period 34.8±16.7 months) patients were classified as non - progressors (n=18; decrease in LVESV <15%), responders (n=41; decrease in LVESV 15-29%) and super - responders (SR) (n=50; reduction in LVESV ≥30%). Results. At baseline groups were matched for main clinical characteristics, the proportion of patients with atrial fibrillation, width of the QRS complex, and the presence of left bundle - branch block. Echocardiographic parameters didn’t differ between the groups. All groups demonstrated significant reverse remodeling of the left ventricle, increase in LVEF, increase in 6-minute walking distance. SR demonstrated the best improvement of clinical and functional parameters after CRT. However, improvement in LVEF, LVESV, NYHA functional class between responders and non - progressors were found similar. Dynamics of these parameters were comparable. The survival rates were 100% in SR, 80% in responders and 88.9% in non - progressors (Log-Rank test p=0.001). Survival rates in responders and non - progressors didn’t differ significantly (Log-Rank test p=0.150). Conclusion. Patients with reduction in LVESV less than 15% demonstrate improvement in clinical status, LVEF and survival rates compared to subjects with reduction in LVESV 15-29%. Non - progressors demonstrate similar survival as responders in long - term period. Taking into account the natural course of CHF functional stabilisation and absence of CHF progression in patients with lack of left ventricular reverse remodelling is a variant of good response and these patients should not be identified as non - responders.
Full Text
##article.viewOnOriginalSite##About the authors
V A Kuznetsov
Tyumen Cardiology Research Center - Branch of Tomsk National Research Medical Center, Russian Academy of ScienceTyumen, Russia
A M Soldatova
Tyumen Cardiology Research Center - Branch of Tomsk National Research Medical Center, Russian Academy of ScienceTyumen, Russia
T N Enina
Tyumen Cardiology Research Center - Branch of Tomsk National Research Medical Center, Russian Academy of ScienceTyumen, Russia
D V Krinochkin
Tyumen Cardiology Research Center - Branch of Tomsk National Research Medical Center, Russian Academy of ScienceTyumen, Russia
S M Dyachkov
Tyumen Cardiology Research Center - Branch of Tomsk National Research Medical Center, Russian Academy of ScienceTyumen, Russia
References
- Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г., Беленков Ю.Н., Васюк Ю.А., Галявич А.С., Гарганеева А.А., Гиляревский С.Р., Глезер М.Г., Козиолова Н.А., Коц Я.И., Лопатин Ю.М., Мартынов А.И. , Моисеев В.С., Ревишвили А.Ш., Ситникова М.Ю., Скибицкий В.В., Соколов Е.И., Сторожаков Г.И., Фомин И.В., Чесникова А.И., Шляхто Е.В. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению хронической сердечной недостаточности (четвертый пересмотр). Сердечная недостаточность. 2013;14(7):379-472.
- Daubert C, Behar N, Martins R.P, Mabo P, Leclercq C. Avoiding non - responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2016;38(19):1463-72. doi: 10.1093/eurheartj/ehw270
- Dhesi S, Lockwood E, Sandhu R.K. Troubleshooting Cardiac Resynchronization Therapy in Non - responders. Can J Cardiol. 2017. doi: 10.1016/j.cjca.2017.04.007
- Van’t Sant J, Mast T.P, Bos M.M, ter Horst I.A, van Everdingen W.M, Meine M, Cramer M.J. Echo response and clinical outcome in CRT patients. Neth Heart J. 2016;24(1):47-55. doi: 10.1007/s12471-015-0767-5
- Кузнецов В.А., Колунин Г.В., Харац В.Е., Криночкин Д.В., Рычков А.Ю., Горбунова Т.Ю. и др. Регистр проведенных операций сердечной ресинхронизирующей терапии. Свидетельство о государственной регистрации базы данных № 2010620077 от 1 февраля 2010 г.
- Priori S.G, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott P.M, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck K.H, Hernandez-Madrid A, Nikolaou N, Norekvål T.M, Spaulding C, van Veldhuisen D.J. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015;17(11):1601-87. doi: 10.1093/europace/euv319
- Maréchaux S, Guiot A, Castel A, Guyomar Y, Semichon M, Delelis F, Heuls S, Ennezat P.V, Graux P, Tribouilloy C. Relationship between Two-Dimensional Speckle-Tracking Septal Strain and Response to Cardiac Resynchronization Therapy in Patients with Left Ventricular Dysfunction and Left Bundle Branch Block: A Prospective Pilot Study. J Am Soc Echocardiogr. 2014;27(5):501-11. doi: 10.1016/j.echo.2014.01.004
- Van’t Sant J, Ter Horst I.A.H, Wijers S.C, Mast T.P, Leenders G.E, Doevendans P.A, Meine M. Measurements of electrical and mechanical dyssynchrony are both essential to improve prediction of CRT response. J Electrocardiol. 2015;48(4):601-8. doi: 10.1016/j.jelectrocard.2015.01.015
- El Missiri A.M. Echocardiographic assessment of left ventricular mechanical dyssynchrony - A practical approach. Egypt Heart J. 2014;66(3):217-25.
- Lang R.M, Badano L.P, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf F.A, Foster E, Goldstein S.A, Kuznetsova T, Lancellotti P, Mu-raru D, Picard M.H, Rietzschel E.R, Rudski L, Spencer K.T, Tsang W, Voigt J.U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-71. doi: 10.1093/ehjci/jev014
- Rickard J, Baranowski B, Wilson Tang W.H, Grimm R.A, Niebauer M, Cantillion D, Varma N. Echocardiographic Predictors of Long-Term Survival in Patients Undergoing Cardiac Resynchronization Therapy: What Is the Optimal Metric? J Cardiovasc Electrophysiol. 2017;28(4):410-5. doi: 10.1111/jce.13175
- Daubert J.C, Saxon L, Adamson P.B, Auricchio A, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow - up recommendations and management. European Heart Rhythm Association (EHRA); European Society of Cardiology (ESC); Heart Rhythm Society; Heart Failure Society of America (HFSA); American Society of Echocardiography (ASE); American Heart Association (AHA); European Association of Echocardiography (EAE) of ESC; Heart Failure Association of ESC (HFA). Europace. 2012;14:1236-86. doi: 10.1093/europace/eus222
- Zhang Q, Zhou Y, Yu C.M. Incidence, definition, diagnosis, and management of the cardiac resynchronization therapy nonresponder. Curr Opin Cardiol. 2015;30(1):40-9.
- Steffel J, Ruschitzka F. Superresponse to Cardiac Resynchronization Therapy. Circulation. 2014;130(1):87-90. doi: 10.1161/CIRCULA-TIONAHA.113.006124
- Friedman D.J, Upadhyay G.A, Rajabali A, Altman R.K, Orencole M, Parks K.A, Singh J.P. Progressive ventricular dysfunction among nonresponders to cardiac resynchronization therapy: Baseline predictors and associated clinical outcomes. Heart Rhythm. 2014;11(11):1991-8. doi: 10.1016/j.hrthm.2014.08.005
- Foley P.W.X, Leyva F, Frenneaux M.P. What is treatment success in cardiac resynchronization therapy? Europace. 2009;11(suppl 5):v58-v65. doi: 10.1093/europace/eup308
- Cleland J.G.F, Ghio S. The determinants of clinical outcome and clinical response to CRT are not the same. Heart Failure Rev. 2012;17(6):755-66. doi: 10.1007/s10741-011-9268-9
- Yu C.M, Bleeker G.B, Fung J.W, Schalij M.J, Zhang Q, Van der Wall E.E, Chan Y.S, Kong S.L, Bax J.J. Left ventricular reverse remodeling but not clinical improvement predicts long - term survival after cardiac resynchronization therapy. Circulation. 2005;112:1580-6. doi: 10.1161/CIR-CULATIONAHA.105.538272
- Ypenburg C, Van Bommel R.J, Borleffs C.J, Bleeker G.B, Boersma E, Schalij M.J, Bax J.J. Long - term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow - up. J Am Coll Cardiol. 2009;53:483-90. doi: 10.1016/j.jacc.2008.10.032
- Кузнецов В.А., Солдатова А.М., Криночкин Д.В., Енина Т.Н. Сердечная ресинхронизирующая терапия при хронической сердечной недостаточности: нужно ли ждать быстрого ответа? Сердечная недостаточность. 2017;18(3):172-7. doi: 10.18087/rhfj.2017.3.2341
- Kirk J.A, Kass D.A. Cellular and molecular aspects of dyssynchrony and resynchronization. Heart Failure Clin. 2017;13(1):29-41. doi: 10.1016/j.hfc.2016.07.003
- Jones S, Lumens J, Sohaib S.A, Finegold J.A, Kanagaratnam P, Tanner M, Mason M. Cardiac resynchronization therapy: mechanisms of action and scope for further improvement in cardiac function. EP Europace. 2016;euw136. doi: 10.1093/europace/euw136
- Cleland J.G.F, Abraham W.T, Linde C, et al. An individual patient meta - analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34(46):3547-56. doi: 10.1093/eurheartj/eht290
- Risum N, Tayal B, Hansen T.F, et al. Identification of typical left bundle branch block contraction by strain echocardiography is additive to electrocardiography in prediction of long - term outcome after cardiac resynchronization therapy. J Am Coll Cardiol. 2015;66:631-41. doi: 10.1016/j.jacc.2015.06.020
- Kuznetsov V, Vinogradova T, Enina T, et al. Influence of atrioventricular junction ablation on survival of patients with congestive heart failure and atrial fibrillation receiving cardiac resynchronisation therapy in real clinical practice. Global Heart. 2014; 9(1):e42-e43.
- Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martine-Ferrer J.B, Proclemer A, Morani G, Biffi M, Ricci R, Rordorf R, Mangoni L, Manotta L, Grammatico A, Leyva F, Boriani G. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter - defibrillator therapies and hospitalizations. Eur J Heart Fail. 2018 Oct;20(10):1472-81. doi: 10.1002/ejhf.1117
![](/img/style/loading.gif)